Last reviewed · How we verify
EV71vac
EV71vac is an inactivated vaccine that stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71 (EV71).
EV71vac is an inactivated vaccine that stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71 (EV71). Used for Prevention of Enterovirus 71 (EV71) infection and hand, foot, and mouth disease (HFMD) in pediatric populations.
At a glance
| Generic name | EV71vac |
|---|---|
| Sponsor | Medigen Vaccine Biologics Corp. |
| Drug class | Inactivated viral vaccine |
| Target | Enterovirus 71 (EV71) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated EV71 virus particles that trigger both humoral (antibody-mediated) and cell-mediated immune responses. This allows the vaccinated individual to recognize and neutralize EV71 upon natural exposure, preventing infection or reducing disease severity. The vaccine is designed to protect against hand, foot, and mouth disease (HFMD) and other serious EV71-associated complications, particularly in pediatric populations.
Approved indications
- Prevention of Enterovirus 71 (EV71) infection and hand, foot, and mouth disease (HFMD) in pediatric populations
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EV71vac CI brief — competitive landscape report
- EV71vac updates RSS · CI watch RSS
- Medigen Vaccine Biologics Corp. portfolio CI